A. Capen

发表

Myostatin Neutralization Results in Preservation of Muscle Mass and Strength in Preclinical Models of Tumor-Induced Muscle Wasting

P. Mitchell, B. Eastwood, V. Wroblewski, 2015, Molecular Cancer Therapeutics.

Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors

D. Timm, R. Walgren, P. Ebert, 2018, Oncotarget.

Absorption and excretion of chromium from orally administered chromium chloride, chromium acetate and chromium oxide in rats

V. Juturu, J. Komorowski, A. Capen, 2003 .

Abstract 2819: Identification and characterization of a novel smoothened antagonist for the treatment of cancer with deregulated hedgehog signaling

P. Hipskind, Hong Gao, K. Credille, 2011 .

Aurora A–Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy

Shobha N. Bhattachar, R. Campbell, Y. Qian, 2019, Molecular Cancer Therapeutics.

The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade.

E. Rasmussen, P. Iversen, M. Kalos, 2018, Cell reports.

Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity.

Tao Wang, Hong Zhang, N. Dean, 2007, The Journal of clinical investigation.

Activating the Wnt/β-Catenin Pathway for the Treatment of Melanoma – Application of LY2090314, a Novel Selective Inhibitor of Glycogen Synthase Kinase-3

T. Engler, K. Rank, J. Atkinson, 2015, PloS one.

The Protein Kinase Cβ–Selective Inhibitor, Enzastaurin (LY317615.HCl), Suppresses Signaling through the AKT Pathway, Induces Apoptosis, and Suppresses Growth of Human Colon Cancer and Glioblastoma Xenografts

R. Campbell, P. Iversen, J. Graff, 2005 .

Preclinical Evaluation and Phase Ib Study of Prexasertib, a CHK1 Inhibitor, and Samotolisib (LY3023414), a Dual PI3K/mTOR Inhibitor

Suzanne F. Jones, J. Bendell, D. Hong, 2021, Clinical Cancer Research.

The Folate Pathway Inhibitor Pemetrexed Pleiotropically Enhances Effects of Cancer Immunotherapy

T. Doman, E. Rasmussen, M. Kalos, 2019, Clinical Cancer Research.

A phase I trial of LY2584702 tosylate, a p70 S6 kinase inhibitor, in patients with advanced solid tumours.

A. Tolcher, K. Papadopoulos, A. Patnaik, 2014, European journal of cancer.

Tasisulam Sodium, an Antitumor Agent That Inhibits Mitotic Progression and Induces Vascular Normalization

G. Evans, M. Uhlik, J. Stewart, 2011, Molecular Cancer Therapeutics.

Abstract 4549: Pemetrexed enhances anti-tumor efficacy of PD1 pathway blockade by promoting intra tumor immune response via immunogenic tumor cell death and T cell intrinsic mechanisms

T. Doman, E. Rasmussen, M. Kalos, 2018, Clinical Research (Excluding Clinical Trials).

Abstract 1131: Novel inhibitor of Notch signaling for the treatment of cancer.

P. Hipskind, Hong Gao, J. Manro, 2013 .